SCHEMBL4415220

SCHEMBL4415220

COc1cc2c(c(OC)c1)C(c1cc(Cl)cc(Cl)c1)N(S(=O)(=O)c1ccc(NC(C)=O)c(Cl)c1)CC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
HCRTR1 O43613 3/20 0.43
HCRTR2 O43614 3/20 0.43
LMNA P02545 3/20 0.43
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM2B Q8NHM5 1/20 0.40
MMP9 P14780 2/20 0.40
MMP2 P08253 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4424185 0.85 LMNA (0.42) ALDH1A1HCRTR1HCRTR2LMNATSHR
SCHEMBL4425699 0.85 TAS2R14 (0.41) ALDH1A1HCRTR1HCRTR2LMNATSHR
SCHEMBL13973166 0.81 TAS2R14 (0.45) HCRTR1HCRTR2MMP9MMP2CA1
SCHEMBL4413279 0.81 TAS2R14 (0.45) HCRTR1HCRTR2MMP9MMP2CA1
SCHEMBL4418789 0.81 VCAM1 (0.47) ALDH1A1LMNACA1CA2CA9
SCHEMBL4412965 0.78 HCRTR1 (0.44) ALDH1A1HCRTR1HCRTR2LMNANPSR1
SCHEMBL13973059 0.78 CA1 (0.49) ALDH1A1LMNANPSR1CA1CA2
SCHEMBL4414625 0.78 CA1 (0.45) ALDH1A1LMNACA1CA2CA9
SCHEMBL4422235 0.77 KDM4E (0.48) ALDH1A1LMNATSHRCA1CA2
SCHEMBL4412007 0.76 MAPT (0.46) LMNACA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663983-B1 N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2009-01-21 EP disclosed
EP-1663983-A1 N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2006-06-07 EP disclosed
US-20050070570-A1 Novel potassium channels modulators 4SC AG (DE) 2005-03-31 US disclosed
WO-2004113302-A1 N-SUBSTITUTED 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070570-A1 Novel potassium channels modulators HCN4, KCNA4, KCNN4 ALDH1A1 3171/4885HCRTR1 281/4885HCRTR2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.